Cardium Therapeutics

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and Tissue Repair Company, are medical technology companies primarily focused on the development, manufacturing, and sale of innovative therapeutic products and devices for cardiovascular, ischemic, and related indications. Cardium’s lead product candidate, Generx (TM) (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapy being developed for use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as refractory angina.